BriaCell reports prelim OS up to 2x literature in ADC-refractory breast cancer subset

BriaCell Therapeutics Corp.

23 heavily pre-treated (median 6 prior therapies) advanced breast cancer patients, all failed ADCs (KADCYLA, ENHERTU, TRODELVY).
Median OS up to twice that reported in comparable studies; 17 of 23 patients remain alive.
Disease control rate of 40% in evaluable patients; PFS similar or better than last regimen in 40%.
No toxicity-related discontinuations and no cases of Interstitial Lung Disease (ILD) with Bria-IMT regimen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.